Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
combination drugs
Biotech
AbbVie’s next-gen Crohn’s combo beats Skyrizi in ph. 2 test
At Week 12, 30.2% of patients treated with the drug combination, dubbed ABBV-466, met the primary endpoint of endoscopic remission.
Nick Paul Taylor
Oct 19, 2026 5:15am
Sionna adds $182M to extend pipeline, cash runway through 2026
Mar 6, 2024 8:00am
Tempest's triplet shows boost over Roche combo in liver cancer
Oct 11, 2023 11:00am
ASCO: Regeneron's Opdualag rival records 61% response rate
May 25, 2023 6:00pm
CureVac rethinks lead cancer program after posting PD-1 data
Nov 16, 2022 8:30am
Virios fails in fibromyalgia but claims efficacy in omicron era
Sep 19, 2022 9:00am
